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Abstract
Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is the most
common and best known monogenic small vessel disease. Here, we review the clinical, neuroimaging,
neuropathological, genetic, and therapeutic aspects based on the most relevant articles published between 1994
and 2016 and on the personal experience of the authors, all directly involved in CADASIL research and care. We
conclude with some suggestions that may help in the clinical practice and management of these patients.
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Background
Cerebral small vessel disease (SVD) is an important
cause of stroke, cognitive impairment, and mood disor-
ders in the elderly. Besides the common sporadic forms,
mostly related to age and hypertension, a minority of
SVD has a monogenic cause, among which the most
common and best known is cerebral autosomal domin-
ant arteriopathy with subcortical infarcts and leukoence-
phalopathy (CADASIL). CADASIL provides a unique
model for the study of the most prevalent forms of spor-
adic SVD. CADASIL is caused by mutations in the
NOTCH3 gene, which maps to the short arm of chromo-
some 19 and encodes the NOTCH3 receptor protein,
predominantly expressed in adults by vascular smooth
muscle cells and pericytes [1]. Thousands of families
with CADASIL have now been diagnosed worldwide in
many different ethnic groups. The disorder is often over-
looked and misdiagnosed. Its minimum prevalence has
been estimated between 2 and 5 in 100,000 but may vary
between populations [2–5].
In this article, we discuss the main clinical, genetic,
neuroimaging, neuropathological, and management as-
pects of the disease.
Methods
The project for this paper was developed following the
9th International Congress on Vascular Dementia, 2015,
held in Ljubljana, Slovenia. Articles published between
1994 to 2016 with the keyword ‘CADASIL’ were re-
trieved from the PubMed database. Figure 1 reports the
number of PubMed articles on CADASIL during the
past years. Only English language papers with high
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scientific relevance were reviewed. In total, 163 articles
related to CADASIL were reviewed and included in the
paper.
Clinical aspects
The main clinical features include migraine usually with
aura presenting in early adulthood [6], recurrent subcor-
tical ischemic events, mood disturbances [7], progressive
cognitive impairment mostly affecting executive function,
and acute encephalopathy [8, 9]. Pescini et al. [10] devel-
oped a score which may be helpful in confirming the clin-
ical suspicion of CADASIL and identifying patients in
whom mutation screening has a reasonable yield.
Migraine
Migraine is often the earliest feature of the disease, being
reported in about 55–75% of Caucasian cases, although
it is less frequent in Asian populations [11]. The age at
onset is highly variable, generally around 30 years [12].
In a recent article on the prevalence and characteristics
of migraine in 378 CADASIL patients [6], a total of
54.5% of individuals had a history of migraine and 84%
of these had migraine with aura (MA). Women with
MA accounted for 62.4% of the total, with an earlier
MA onset compared to men. Atypical auras, such as
prolonged visual auras, gastrointestinal manifestations,
dysarthria, confusion, focal neurologic deficits, and other
uncommon manifestations, were experienced by 59.3%
of individuals with MA, and in 19.7% of patients the
aura was sine migraine. MA was the first clinical mani-
festation in 41% of symptomatic patients and an isolated
symptom in 12.1%. The pathophysiological reasons
leading to increased aura prevalence in CADASIL are
unknown; a possible mechanism is an increased suscep-
tibility to cortical spreading depression [13]. It is also
possible that migraine in CADASIL involves the brain-
stem region. Alternatively, the NOTCH3 mutation itself
may act as a MA susceptibility gene [14].
Subcortical ischemic events
Transient ischemic attacks and stroke are reported in
approximately 85% of symptomatic individuals [15] and
are related to cerebral small vessel pathology. Mean
age at onset of ischemic episodes is approximately
45–50 years [16], but the range at onset is broad (3rd
to 8th decade).
Ischemic episodes typically present as a classical lacu-
nar syndrome (pure motor stroke, ataxic hemiparesis/
dysarthria-clumsy hand syndrome, pure sensory stroke,
sensorimotor stroke), but other lacunar syndromes
(brain stem or hemispheric) are also observed. The total
lacunar lesion load, symptomatic and asymptomatic, is
strongly associated with the development of severe
disability with gait disturbance, urinary incontinence,
pseudobulbar palsy and cognitive impairment. Strokes
involving the territory of a large artery have occasionally
been reported but whether these are co-incidental or
related to the CADASIL pathology itself is uncertain
[17–19]. There have been a few cases of subcortical
hemorrhage, mostly in patients taking anticoagulants.
Encephalopathy
An acute encephalopathy [20] has been described in 10%
of CADASIL patients, and in the majority of these it was
the first major symptom, with a mean age of onset of 42
years [9]. It is frequently misdiagnosed as encephalitis,
particularly if it is the initial presentation in a patient
without known CADASIL. It usually evolves from a
migraine attack, including confusion, reduced con-
sciousness, seizures, and cortical signs, with spontan-
eous resolution.
Cognitive impairment in CADASIL first involves infor-
mation processing speed and executive functions, with
relative preservation of episodic memory, and is associ-
ated with apathy and depression [21–25]. Memory im-
pairment has been reported, particularly later in the
disease. Cognitive screening measures, as the Brief
Memory and Executive Test and the Montreal Cognitive
Assessment, are clinically useful and sensitive screening
measures for early cognitive impairment in patients with
CADASIL [26]; 3-year changes in Mini Mental State
Examination, Mattis Dementia Rating Scale, Trail
Making Test version B, and modified Rankin Scale are
validated models for prediction of clinical course in
CADASIL [27]. The cognitive deficits were initially at-
tributed to subcortical origin [28]. More recently, the
cerebral cortex was shown also to be affected in
CADASIL [29] by direct mechanisms (cortical microin-
farcts [30]), or through secondary degeneration [31].
Memory impairment in CADASIL is probably related to
different causes, due to both white matter infarcts with
disruption of either cortico-cortical or subcortical-
cortical networks mainly in the frontal lobe and primary
Fig. 1 Results on PubMed search by years 1993–2016
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damage of the cortex [32, 33]. In a recent longitudinal
study, processing speed slowing was related to a de-
crease of sulcal depth, but not to global brain atrophy
or cortical thinning, suggesting that early cognitive
changes may be more specifically related to sulcal
morphology than to other anatomical changes [34].
Moreover, studies in mouse models of CADASIL have
detected dysregulation of hippocampal neurogenesis, a
process essential for the integration of new spatial
memory records [35].
Psychiatric disturbances
Although the clinical expression of the disease is mainly
neurological, CADASIL is also characterized by psychi-
atric disturbances (20–41%) [36, 37]. Apathy and major
depression are commonly observed in CADASIL. Also
bipolar disorder and emotional incontinence are present
in a consistent percentage of patients [38]. The direct
consequence is a negative effect on patient’s quality of
life and caregiver burden, with different degrees. Other
psychiatric manifestations, such as psychotic disorders,
adjustment disorders, personality disorders, drug addic-
tion, and abuse of substances, are less frequent. The
pathogenesis of psychiatric disturbances in CADASIL is
incompletely understood, but, similarly to other cerebro-
vascular diseases, may depend on the damage of the
cortical–subcortical circuits, leading to the consideration
of mood disorders in CADASIL under the concept of
‘vascular depression’.
In conclusion, CADASIL symptoms may be highly
variable, usually starting in adulthood, but also reported
in older age [39]. The wide clinical spectrum includes
complex migraine attacks with prominent aura, acute
confusional states or coma, lacunar strokes, and pure
psychiatric or cognitive presentations. Ischemic events,
in different brain areas, may involve also the optic nerve
[40]; retinal involvement is also described [41, 42]. Few
reports also suggest the presence of myopathy or periph-
eral neuropathy, the first possibly related to involvement
of mitochondrial dysfunctions, but these findings may be
coincidental. Typical and atypical phenotypes are re-
ported in Table 1.
Modulating factors
CADASIL is characterized by a large phenotypic
variability both across and within families. No clear
genotype–phenotype correlation has been found to date
[43] and both modulating genetic and risk/environmental
factors probably play a role.
Among the conventional risk factors, hypertension
and smoking are associated with early age of onset of
stroke [9, 43, 44] and with clinical worsening towards
dementia [45, 46]. In a recent longitudinal study, smok-
ing was associated with a three-fold increase in stroke
risk [46]. Homocysteine levels have been found to be
higher in patients with CADASIL who have migraine,
but this finding needs replicating [43].
Opherk et al. [47, 48] found that white matter le-
sion volumes are influenced by genetic factors distinct
from the causative NOTCH3 mutation, but the nature
of the responsible modulating genetic factors is
currently unknown. The role of Apolipoprotein E
(APOE) is debated – Gesierich et al. [49] suggested a
modifying influence of APOE ɛ2 on the volume of
white matter hyperintensities, while Singhal et al. [43]
detected no relationship between phenotype and
APOE ɛ4 genotype.
Gunda et al. [50] hypothesized on a possible role of
ovarian hormones in sex-related differences in CADA-
SIL, data that need further confirmation.
Recently, Pescini et al. [51] evaluated a possible role of
plasma levels of von Willebrand factor, blood levels of
endothelial progenitor cells, and endothelial impairment
in the pathogenesis of the disease.
Table 1 Typical and atypical clinical manifestations of CADASIL
Typical manifestations
Migraine, usually with aura, as the first symptom in the third
decade of life
Recurrent subcortical ischemic events (transient ischemic attack/
stroke) in adulthood
Mood disturbances, apathy and depression among other psychiatric
symptoms
Progressive cognitive decline, especially of executive functioning
Seizures, in a smaller but well-defined portion of patients
Atypical manifestations
Pathological gambling [128]
Recurrent status epilecticus [129]
Schizopheniform organic psychosis [130, 131]
Neuropathy [132–134]
Myopathy [100, 135–138]
‘CADASIL coma’ [25, 139]




Acute vestibular syndrome [144]
Spinal cord involvement [145, 146]
Acute confusional migraine [147]
Sporadic hemiplegic migraine with normal imaging [148]
Post-partum psychiatric disturbances [149]
Parkinsonism [150]
Recurrent transient global amnesia [151]
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Life expectancy, cause of death, and
cardiovascular aspects
Life expectancy is reduced in CADASIL patients. An age
at death in men of 64.6 years and in women of 70.7
years has been reported in a large study of 411 subjects
[16]. Pneumonia in patients with disability was the major
cause of death (38%), but a high number of sudden un-
expected deaths were also observed, accounting for up
to 26% [16]. Whether cardiac arrhythmias, QT variability
index, and myocardial infarction are more frequent in
CADASIL than in the general population remains to be
confirmed [52–55].
Another point of interest is the finding of a non-
dipper pattern of nocturnal blood pressure [56]. A lower
nocturnal blood pressure fall may be associated with in-
cidence and/or worsening of deep white matter lesions
in CADASIL. The pathogenesis of abnormal blood pres-
sure profile in CADASIL remains to be clarified. Central
and peripheral mechanisms controlling blood pressure
variations may be involved.
The association between CADASIL and right-to-left
cardiac shunt has been reported but remains under
debate [57, 58].
Neuroimaging
Cerebral Magnetic Resonance Imaging (MRI) in CADA-
SIL shows age- and disease stage-dependent extensive
white matter abnormalities, seen as large symmetrical
hyperintense signals on T2-weighted and FLAIR im-
ages [59], and lacunes, i.e., fluid-filled cavities with
cerebrospinal fluid-isointense signal. Diffusion-weighted
imaging may show acute and subacute infarctions, and
can also be used to quantify chronic white matter
changes through diffusion tensor metrics. White mat-
ter changes often involve the anterior temporal lobe,
the external capsule and the superior frontal gyrus
[60]. Anterior temporal pole changes have been
shown to have a high sensitivity and specificity for
the disease (approximatively 90% for each) and are
useful in diagnosis [61]. In Asian populations, anterior
temporal lobe involvement is less common [62]. Ex-
ternal capsule changes also have a high sensitivity
(approximatively 90%) but a lower specificity (ap-
proximately 50%). In fact, a recent systematic analysis
showed a similar involvement of the external capsule
in CADASIL and sporadic SVD [63]. Corpus callosal
signal abnormalities, rarely occurring in sporadic
SVD, are described in CADASIL [59] (Fig. 2); such
abnormalities are also a feature of multiple sclerosis,
which is one reason for the misdiagnosis of CADASIL
as multiple sclerosis. Cerebral microbleeds, which are
shown by Gradient-echo images with dot-like hypoin-
tense lesions, occur in a variable proportion of cases
(30–70%) and usually increase with age and risk factors
such as high blood pressure, and intracerebral hemorrhage
have also been described in a number of patients [64–66],
especially those of Asian origin [67]. Nevertheless, the clin-
ical significance of the cerebral microbleeds observed in
CADASIL has not been clearly elucidated.
MRI white matter signal abnormalities are found in
presymptomatic CADASIL mutation carriers aged 20–
30 years or older [59, 68].
The MRI findings that have been most strongly related
to clinical deficit are number and volume of lacunes,
Fig. 2 Axial FLAIR MRI: Multifocal/confluent subcortical white matter lesions, with involvement of anterior temporal lobes (a, b), pons (a), external
capsules, periventricular and fronto-pariental regions (c), and corpus callosum (d)
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brain atrophy, and white matter damage as assessed by
diffusion tensor imaging [69, 70]. CADASIL has primar-
ily been defined as a subcortical disease, but recent stud-
ies with high-field 7-Tesla MRI, which allows higher
resolution imaging, have detected primary involvement
of the cortex, including the demonstration of cortical
microinfarcts and early diffuse cortical alterations [23] in
frontal and parietal regions most often following a sym-
metrical pattern in both hemispheres. These changes
were not related to cortical thinning or to subcortical le-
sions and have been hypothesized to be secondary to
venous vascular density or intramyelin edema [71]. Simi-
lar data have also been reported in experimental models
[72]. Moreover, subcortical changes might induce sec-
ondary cortical changes [69, 72–74]. In a longitudinal
study, incident lacunes were followed by cortical thin-
ning specifically in connected brain regions [31]. An-
other recent development is the use of diffusion tensor
imaging to characterize tissue damage [75, 76]. The typ-
ical change in diffusion metrics observed in CADASIL
patients is a reduction in fractional anisotropy (a meas-
ure for the directionality of diffusion) and an increase in
the apparent diffusion coefficient or mean diffusivity (a
measure for the extent of diffusion) [69, 77]. Histogram
analysis has been proposed as a sensitive tool to measure
CADASIL-related changes cross-sectionally as well as
longitudinally [78–80].
Neuropathology
The pathological hallmark of CADASIL is deposition of
granular osmiophilic material (GOM) in close relation to
vascular smooth muscle cells, seen on electron micros-
copy. GOM can also be detected in vessels of extracer-
ebral tissues, including skin and muscle. Consequently,
skin biopsy has been considered an important diagnostic
tool [81], with a specificity of 100%, and variable sensi-
tivity from 45% to 100% according to the different re-
ports [82–84]. The reasons for this discrepancy may be
related to different factors, including different stages of
the disorder, the size of the biopsy and the number of ar-
teriolar and precapillary vessels in the specimen, or the
focality of lesions. It is also important to differentiate
GOM from dense bodies and non-specific granular deb-
ris present in degenerated smooth muscle cells. The rea-
son why the small-to-medium sized cerebral arteries are
most severely affected and why there are no extra-
cerebral clinical disease manifestations is still not fully
understood. Further, the composition of GOM remains
partly unclear. Previous immunoelectron microscopy
studies reported the accumulation of the NOTCH3 ecto-
domain in proximity of GOM formation [85]. More re-
cent investigation by post-embedding immunoelectron
microscopy analysis using antibodies against the extra-
and intracellular portions of NOTCH3, showed the
NOTCH3 ectodomain to be a major component of
GOM [86–88]. Immunohistochemistry analysis using a
NOTCH3 monoclonal antibody was proposed as a fur-
ther reliable tool for CADASIL diagnosis [89]. Although
high specificity and sensitivity, ranging from 90% to
100%, were reported, this high level of accuracy has not
been reported by any other group and the technique is
not currently widely used in diagnosis [90].
In conclusion, preferably, skin biopsy analysis should
include both NOTCH3 immunohistochemistry and elec-
tron microscopy. For electron microscopy analysis at
least 4–6 arteriolar vessels for each patient should be ex-
amined. In most CADASIL centers, skin biopsy is only
reserved in those cases with suspected CADASIL, but
who did not have a NOTCH3 mutation or who had an
unclassified variant in NOTCH3. Genetic testing is be-
coming an increasingly accessible diagnostic tool and, in
patients with a clinical suspicion of CADASIL, NOTCH3
Sanger sequencing of EGFr encoding exons, if available,
is the first choice for confirming the clinical diagnosis.
This has the added advantage that testing of family
members (both symptomatic and asymptomatic) is feas-
ible once the mutation is known in the index patient.
There are few brain neuropathological analyses pub-
lished in CADASIL, and these have mainly focused on
cerebral vessel changes that are reported to be consist-
ently narrowed with intimal thickening and degeneration
of vascular smooth muscle cells and GOM deposition
[91]. In 11 patients, Craggs et al. [92] reported disrup-
tion of either cortico-cortical or subcortico-cortical net-
works in the white matter of the frontal lobe, explaining
motor deficits and executive dysfunction present in
CADASIL.
Genetics
NOTCH3 is the causative gene for CADASIL, which
maps to the short arm of chromosome 19 (19p13.2-
p13.1) [1, 93]. It is a large gene containing 33 exons [94].
The NOTCH3 gene codes for a single-pass transmem-
brane receptor protein, with a large extracellular
domain, with 34 EGFRs (tandem epidermal growth
factor-like repeat domains) and 3 LNR repeats, a trans-
membrane portion and an intracellular domain contain-
ing ankyrin-repeat motifs and a PEST domain [95].
NOTCH3 protein is expressed in vascular smooth
muscle cells, whose degeneration results in progressively
impaired cerebrovascular autoregulation, hypoperfusion,
and ischemia [84]. More than 200 different NOTCH3
gene CADASIL-associated mutations have been re-
ported, the majority of them consisting of stereotyped
missense substitutions of a single base leading to loss or
gain of a cysteine residue within one of the EGFRs of
NOTCH3 extracellular domain [96]. Initially, most muta-
tions were found to cluster in exons 3 and 4, but there
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are now many reports of mutations in other exons encod-
ing the extracellular portion of the protein [2, 39, 97, 98].
Therefore, screening should include all EGFR encoding
exons (exon 2–24). A few patients are reported with
homozygous or compound heterozygous (Dotti unpub-
lished data, [99]) NOTCH3 mutations; in these patients,
the phenotype is almost always within the classical
CADASIL spectrum [100–105].
Whether non-cysteine variants can cause CADASIL is
debated. Small NOTCH3 deletions, duplications, splice
site mutations, and deletion/insertions associated with
CADASIL have been described. Most of these mutations
lead to a numerical cysteine acid change [106]. In one
study, a small intronic deletion leading to intron 3 reten-
tion was found to be associated with a GOM-positive
CADASIL patient; the 25 additional amino acids in the
EGFR likely disturb the disulphide bond formation
[107]. Several studies have reported atypical, cysteine-
sparing, NOTCH3 mutations associated with a familial
CADASIL phenotype. These variants may be interpreted
as causative mutations only if the complete screening of
the EGFR-encoding exons excludes other classic muta-
tions and GOM are present in skin biopsy [106, 108, 109].
However, one study suggested that GOM analysis might
be less sensitive in patients with non-cysteine involving
mutations [110].
Mutations causing loss of function (frame-shift deletion
or nonsense mutations) are rarely reported in CADASIL
patients, and their role is still debated [106, 111, 112]; they
should be carefully analyzed to determine their pathogen-
icity. NOTCH3 mutations located outside of the EGFR en-
coding exons, reported in few cases, are not associated
with a CADASIL phenotype [113–115].
A simple flow chart for CADASIL diagnosis is shown
in Fig. 3.
Genetic counseling
Genetic counseling should be offered to all patients diag-
nosed with CADASIL and should always precede
predictive genetic testing of family members. For pre-
dictive genetic testing, the Huntington’s disease guide-
lines can be used [116, 117]. It is important to note
that a MRI scan in an unaffected family member can
have a similar impact as a genetic test if it shows the
characteristic MRI hallmarks of the disease. Genetic
counselling also plays an important role in family
planning and questions about options for prenatal
diagnosis or pre-implantation genetic diagnosis may
be discussed in countries where these techniques are
available [118, 119].
Treatment
An effective treatment for CADASIL is not available. In
the absence of curative approaches, treatments should
be directed towards the search of possible disease-
modifying strategies to mitigate clinical manifestations
[120]. The review of available data shows that only a few
and very preliminary studies have been reported thus
far. In Tables 2 and 3, we summarized studies focused
on symptomatic outcomes and those focused on cerebral
and peripheral blood flow changes with a possible effect
on disease mechanisms.
In view of the evidence of a more severe disease
course in individuals with vascular risk factors, particu-
larly smoking and hypertension, control of vascular risk
factors is an important part of CADASIL management.
Concerning the use of antiplatelet drugs, such as aspirin
or clopidogrel, most neurologists apply the guidelines
used for sporadic stroke when treating CADASIL pa-
tients. However, the appropriateness of this approach is
undetermined. In fact, the thrombotic genesis of ische-
mic events in this disease has not been proven so far.
On the other hand, many reports have stressed the
presence of microhemorrhages (microbleeds) in a
considerable percentage of CADASIL patients [121].
For these reasons, the safety of antiplatelet drugs in
this disease remain to be clarified [65]. Similarly, the
benefit of thrombolysis is uncertain, although it has
been suggested that it is of benefit in sporadic lacu-
nar stroke [122].
Following the data reported by Keverne et al. [121]
showing a cholinergic neuronal impairment in CADASIL,
a multicenter trial in 168 patients with donepezil was
performed; this showed no improvement in the pri-
mary outcome of the Vascular Dementia Assessment
scale – cognitive subscale. Improvements were noted
on several measures of executive function, but the
clinical relevance of these findings is not clear [123].
Complications of CADASIL, such as depression and
migraine, appear to respond to similar treatments to
those used in sporadic disease, although further stud-
ies are required to determine the efficacy of these ap-
proaches in CADASIL patients.
Fig. 3 Flow-chart for CADASIL diagnosis
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Differential diagnosis
A differential diagnosis in some cases may be hard.
However, in CADASIL, in comparison to multiple scler-
osis, temporo-polar MRI lesions are present in a high
percentage, the optic nerve and spinal cord are generally
not involved, and oligoclonal bands in the cerebrospinal
fluid are absent. Corpus callosum hyperintensities are
described both in CADASIL and in multiple sclerosis
[124, 125]. In relation to cerebral autosomal dominant
arteriopathy with subcortical infarcts and leukoencepha-
lopathy (CARASIL), in CADASIL, extraneurological
findings (early-onset spondylosis and early-onset alopecia)
are absent, clinical onset is generally later, MA is a typical
sign, and inheritance is autosomal dominant [126]. Other
hereditary leukoencephalopathies to take into account for
a correct differential diagnosis are MELAS, Krabbe dis-
ease, Fabry disease, CARASAL, hereditary diffuse leu-
koencephalopathy with axonal spheroids, and other more
rare monogenic forms of SVD [127].
Highlights and key questions for management of
CADASIL patients
– Clinical presentation: The clinical presentation is
usually stereotyped with MA, small subcortical
strokes, or cognitive impairment in middle-aged
patients with a family history of stroke or dementia,
but the spectrum of the disease is wide and atypical
phenotypes have been reported. There is wide
variation in phenotype both within and between
families.
– Cognitive impairment: Cognitive impairment is a
prominent feature in CADASIL. While its clinical
pattern is typically subcortical, several recent data
suggest that the cerebral cortex is also involved and
contributes to the cognitive profile abnormalities.
– Brain MRI: Cerebral MRI in CADASIL shows
extensive white matter changes, with frequent
involvement of temporal pole and external
capsule. No abnormality is pathognomonic, but
confluent bilateral anterior temporal pole T2-
hyperintensities are highly suggestive. Recent
advances in neuroimaging have also revealed
involvement of the cortex.
– Vascular risk factors: Smoking seems to be clearly
associated with an increase in the stroke risk both in
cross-sectional and longitudinal studies. Moreover,
smoking and hypertension are associated with an
earlier onset of stroke and more rapid progression in
CADASIL. Evidence is less robust for other risk
factors and more study is needed. However, in the
absence of effective therapeutic approaches, control
of vascular risk factors is recommended. Also,
genetic modulating factors other than the NOTCH3
mutation probably play a role, but their nature
remains to be determined.
– Genetic: More than 200 different NOTCH3 gene
mutations have been reported in exons 2–24,
involving the loss or gain of cysteine residues. The
role of non-canonic NOTCH3 mutations (e.g.,
cysteine-sparing mutations, mutations outside EGFR
domains, frameshift or nonsense mutations) is
Table 2 Symptomatic treatment in CADASIL
Symptom Therapy Effects
Migraine Acetazolamide [152–154] As prophylaxis, reduces the frequency of migraine attacks
Sodium valproate [155] Anecdotal cases
Cognitive decline Acetylcholinesterase inhibitor [121] Not efficacious on the primary end-point (Vascular Dementia
Assessment scale after 18 weeks), but some improvement in
relation to frontal-subcortical dysfunction
Primary and secondary stroke prevention Antiplatelet drugs [66, 123] Unproven and debated benefits
Table 3 Therapeutic studies on blood flow in CADASIL
Drug Effect
Acetazolamide Related to an increase of cerebral perfusion evaluated by perfusion MRI [156],
transcranial Doppler sonography [157] and Tc-99 m extracellular domain brain
perfusion SPECT [158, 159]
Atorvastatin No effects on cerebral blood flow [160], tested with transcranial Doppler
L-arginine Induced-vasoreactivity [161], tested with transcranial Doppler
Sapropterin (200–400 mg bid in 24 months) Final results for the primary end-point (mean difference in reactive hyperemia index)
were not significant for any improvement of peripheral vasoreactivity [162]
Novel molecular therapeutic target (as stem cell factor and
granulocyte-colony stimulating factor)
Ongoing [163]
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debated; in these cases, the search for GOMs in
skin is mandatory, although in some cases it may
be negative. When identifying a non-canonic
mutation, sequencing of all EGFR-encoding exons
of the NOTCH3 gene is mandatory as well as the
cosegregation analysis of the non-canonic mutation
with the CADASIL MRI phenotype within the family.
– Neuropathology: GOM is the neuropathological
hallmark of CADASIL. Specificity is high, but
sensitivity is variable. Mutation testing is the gold
standard, and the use of skin biopsy should be
limited to the rare situations when the diagnosis is
strongly suspected despite negative genetic testing.
– Genetic counseling: Genetic counseling should
always be offered to patients diagnosed with
CADASIL and should precede all predictive genetic
testing. Predictive genetic testing should only be
offered to adults (>18 years) and should be
performed by trained staff with genetic counselling
experience, using a standard protocol such as that
used in Huntington’s disease.
– Treatment: In the absence of specific data for
CADASIL, most neurologists use aspirin in
secondary prevention after ischemic strokes in older
patients, for example, those aged over 40, but there
is no evidence for or against its use. Whether this
strategy is appropriate in CADASIL is undetermined
and will require further investigation, given the
possible increased hemorrhagic risk. Patients that
need to undergo anticoagulation for a clear
indication such as high risk atrial fibrillation should
be carefully followed given the reported risk of
intracerebral hemorrhage. A multicenter randomised
controlled trial using donepezil to improve cognitive
dysfunction showed no benefit on the primary
endpoint and only improvements of uncertain clinical
significance on several measures of executive function.
New, rational therapeutic interventions for CADASIL
are in early phases of pre-clinical development.
Conclusions
CADASIL is the most frequent monogenic cerebral
SVD, and has received a lot of attention in recent
years as a model for SVD, with an increased number
of cases. However, more work remains to be done in
order to better explore the underlying mechanism of
its pathogenesis. The studies on animal models (see
elsewhere in this issue) will improve the understand-
ing of the pathogenic mechanisms and may open new
therapeutic strategies.
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